Logo image of CELZ

CREATIVE MEDICAL TECHNOLOGY (CELZ) Stock Fundamental Analysis

NASDAQ:CELZ - Nasdaq - US22529Y4089 - Common Stock - Currency: USD

5.4  -0.59 (-9.85%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CELZ. CELZ was compared to 572 industry peers in the Biotechnology industry. While CELZ has a great health rating, there are worries on its profitability. CELZ is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CELZ had negative earnings in the past year.
CELZ had a negative operating cash flow in the past year.
In the past 5 years CELZ reported 4 times negative net income.
CELZ had a negative operating cash flow in each of the past 5 years.
CELZ Yearly Net Income VS EBIT VS OCF VS FCFCELZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M -20M -30M

1.2 Ratios

CELZ has a Return On Assets of -77.21%. This is in the lower half of the industry: CELZ underperforms 67.85% of its industry peers.
Looking at the Return On Equity, with a value of -81.10%, CELZ is in line with its industry, outperforming 51.87% of the companies in the same industry.
Industry RankSector Rank
ROA -77.21%
ROE -81.1%
ROIC N/A
ROA(3y)22.76%
ROA(5y)-1315.51%
ROE(3y)24.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CELZ Yearly ROA, ROE, ROICCELZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2K -2K -4K

1.3 Margins

With a decent Gross Margin value of 60.00%, CELZ is doing good in the industry, outperforming 79.22% of the companies in the same industry.
In the last couple of years the Gross Margin of CELZ has grown nicely.
The Profit Margin and Operating Margin are not available for CELZ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.44%
GM growth 5Y7.57%
CELZ Yearly Profit, Operating, Gross MarginsCELZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20K -20K -40K -60K

More info and screens

8

2. Health

2.1 Basic Checks

CELZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
CELZ has less shares outstanding than it did 1 year ago.
CELZ has more shares outstanding than it did 5 years ago.
CELZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CELZ Yearly Shares OutstandingCELZ Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M
CELZ Yearly Total Debt VS Total AssetsCELZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

CELZ has an Altman-Z score of 2.73. This is not the best score and indicates that CELZ is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of CELZ (2.73) is better than 73.36% of its industry peers.
There is no outstanding debt for CELZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.73
ROIC/WACCN/A
WACC9.44%
CELZ Yearly LT Debt VS Equity VS FCFCELZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M -20M -30M

2.3 Liquidity

CELZ has a Current Ratio of 19.13. This indicates that CELZ is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 19.13, CELZ belongs to the best of the industry, outperforming 94.14% of the companies in the same industry.
A Quick Ratio of 19.12 indicates that CELZ has no problem at all paying its short term obligations.
CELZ has a better Quick ratio (19.12) than 94.14% of its industry peers.
Industry RankSector Rank
Current Ratio 19.13
Quick Ratio 19.12
CELZ Yearly Current Assets VS Current LiabilitesCELZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 51.54% over the past year.
CELZ shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -63.33%.
CELZ shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -40.43% yearly.
EPS 1Y (TTM)51.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.47%
Revenue 1Y (TTM)-63.33%
Revenue growth 3Y-61.68%
Revenue growth 5Y-40.43%
Sales Q2Q%-100%

3.2 Future

CELZ is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.28% yearly.
The Revenue is expected to grow by 554.88% on average over the next years. This is a very strong growth
EPS Next Y11.82%
EPS Next 2Y17.51%
EPS Next 3Y8.14%
EPS Next 5Y30.28%
Revenue Next Year33.33%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y554.88%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CELZ Yearly Revenue VS EstimatesCELZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M 100M
CELZ Yearly EPS VS EstimatesCELZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 20 40 60 80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CELZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CELZ. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CELZ Price Earnings VS Forward Price EarningsCELZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CELZ Per share dataCELZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.51%
EPS Next 3Y8.14%

More info and screens

0

5. Dividend

5.1 Amount

CELZ does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CREATIVE MEDICAL TECHNOLOGY

NASDAQ:CELZ (2/21/2025, 8:07:09 PM)

5.4

-0.59 (-9.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-08 2024-11-08/amc
Earnings (Next)03-20 2025-03-20/amc
Inst Owners1.75%
Inst Owner Change-56.84%
Ins Owners0.81%
Ins Owner Change0%
Market Cap9.45M
Analysts82.86
Price Target30.6 (466.67%)
Short Float %2.36%
Short Ratio0.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.03%
Min EPS beat(2)-29.55%
Max EPS beat(2)13.49%
EPS beat(4)2
Avg EPS beat(4)4.62%
Min EPS beat(4)-29.55%
Max EPS beat(4)37.77%
EPS beat(8)4
Avg EPS beat(8)-75.11%
EPS beat(12)5
Avg EPS beat(12)-190.3%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)47.06%
EPS NY rev (1m)0%
EPS NY rev (3m)3.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 859.09
P/FCF N/A
P/OCF N/A
P/B 1.44
P/tB 1.57
EV/EBITDA N/A
EPS(TTM)-3.78
EYN/A
EPS(NY)-2.28
Fwd EYN/A
FCF(TTM)-3.06
FCFYN/A
OCF(TTM)-3
OCFYN/A
SpS0.01
BVpS3.75
TBVpS3.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.21%
ROE -81.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60%
FCFM N/A
ROA(3y)22.76%
ROA(5y)-1315.51%
ROE(3y)24.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.44%
GM growth 5Y7.57%
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.13
Quick Ratio 19.12
Altman-Z 2.73
F-Score5
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.47%
EPS Next Y11.82%
EPS Next 2Y17.51%
EPS Next 3Y8.14%
EPS Next 5Y30.28%
Revenue 1Y (TTM)-63.33%
Revenue growth 3Y-61.68%
Revenue growth 5Y-40.43%
Sales Q2Q%-100%
Revenue Next Year33.33%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y554.88%
EBIT growth 1Y44.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.42%
OCF growth 3YN/A
OCF growth 5YN/A